Effect of esketamine on opioid consumption and postoperative pain in thyroidectomy: A randomized controlled trial
British Journal of Clinical Pharmacology · 2023-08 · 89 (8) · 2542-2551
DOI: 10.1111/bcp.15726 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 16.04.2023. Verfasst von Penglei Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Analgesics, Opioid, Sufentanil. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Aims
Thyroidectomy is frequently associated with substantial postoperative pain. Esketamine, an N ‐methyl‐ d ‐aspartate receptor antagonist, has been demonstrated to be effective in multiple analgesia scenarios. We hypothesized that intraoperative administration of esketamine may reduce perioperative opioid consumption and postoperative pain in patients undergoing thyroidectomy.
Methods
Sixty patients undergoing thyroidectomy were randomly assigned to two groups. Patients in the esketamine group received a pre‐incisional intravenous bolus of esketamine (0.5 mg kg −1 ) followed by a continuous infusion of 0.24 mg kg −1 h −1 until the beginning of wound closure. Patients in the placebo group received 0.9% NaCl (bolus and infusion). The primary outcome was perioperative sufentanil consumption. The postoperative pain, sleep quality and adverse events during the first postoperative 24 h were also evaluated.
Results
Patients in the esketamine group consumed significantly less sufentanil than those in the saline group (24.6 ± 3.1 μg vs . 33.7 ± 5.1 μg, mean difference, 9.1; 95% confidence interval [CI], 6.9–11.3, P < .001). Postoperative pain scores were significantly lower in the esketamine group than those in the saline group during the first 24 h postoperatively ( P < .05). Patients receiving esketamine experienced higher sleep quality than those in the saline group during surgical night ( P = .043). There were no significant differences in adverse events between the two groups.
Conclusions
Intraoperative administration of esketamine reduces perioperative sufentanil consumption and postoperative pain without increasing psychotomimetic side effects in patients undergoing thyroidectomy. The development of combined anaesthesia regimens, including esketamine, may foster strategies for pain management during thyroidectomy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
ORCID-Profile: Yun Wu
Zitieren
APA
Wang, P., Song, M., Wang, X., Zhang, Y., & Wu, Y. (2023). Effect of esketamine on opioid consumption and postoperative pain in thyroidectomy: A randomized controlled trial. British Journal of Clinical Pharmacology, 89(8), 2542-2551. https://doi.org/10.1111/bcp.15726
Vancouver
Wang P, Song M, Wang X, Zhang Y, Wu Y. Effect of esketamine on opioid consumption and postoperative pain in thyroidectomy: A randomized controlled trial. British Journal of Clinical Pharmacology. 2023;89(8):2542-2551. doi:10.1111/bcp.15726
BibTeX
@article{Wang2023,
author = {Wang, Penglei and Song, Meixian and Wang, Xiaoli and Zhang, Ye and Wu, Yun},
title = {Effect of esketamine on opioid consumption and postoperative pain in thyroidectomy: A randomized controlled trial},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
volume = {89},
number = {8},
pages = {2542--2551},
doi = {10.1111/bcp.15726}
}
EUVIMED